Skip to main content

Advertisement

Table 1 Characteristics of breast cancer cases and controls, matched on age, menopausal status, and MBI year

From: Background parenchymal uptake on molecular breast imaging as a breast cancer risk factor: a case-control study

Characteristic Breast cancer cases (n = 62) Controls (n = 179) p value
Age at MBI,ayears 60.3 ± 10.6 (38–86) 60.2 ± 10.6 (38–88) 0.88
Menopausal status    N/Ab
 Premenopausal 13 (21) 38 (21)  
 Postmenopausal 49 (79) 141 (79)  
BMIa 27.7 ± 6.4 (18.8–55.5) 26.2 ± 4.6 (18.6–44.3) 0.08
Postmenopausal systemic HRTc    0.57
 Current use at MBI 13 (27) 44 (31)  
 No current use at MBI 36 (73) 97 (69)  
BI-RADS density    0.77
 Almost entirely fat 1 (2) 3 (2)  
 Scattered fibroglandular densities 10 (16) 34 (19)  
 Heterogeneously dense 44 (71) 114 (64)  
 Extremely dense 7 (11) 26 (15)  
 Unknown 0 2 (1)  
Percentage densitya 24.8 ± 8.3 (3.5–48.0) 24.6 ± 10.2 (1.8–53.8) 0.92
MBI protocol    0.88
 740 MBq Tc-99m sestamibi 36 (58) 102 (57)  
 240–300 MBq of Tc-99m sestamibi 26 (42) 77 (43)  
Tumor invasiveness    
 Invasive 45 (73) NA  
 DCIS 17 (27) NA  
Gail model 5-year riska 2.7 ± 1.5 (0.6–7.2) 2.4 ± 1.5 (0.5–9.5) 0.23
BCSC model 5-year riska 2.6 ± 1.2 (0.7–5.4) 2.3 ± 1.5 (0.4–13.2) 0.29
Family history of breast cancer    0.45
 One or more first-degree relatives 33 (53) 86 (48)  
 No first-degree relatives 29 (47) 93 (52)  
Personal history of biopsy showing atypia or LCIS    0.07
 Yes 6 (10) 6 (3)  
 No 56 (90) 173 (97)  
  1. BCSC Breast Cancer Surveillance Consortium, BI-RADS Breast Imaging-Reporting and Data System, BMI body mass index, DCIS ductal carcinoma in situ, HRT hormone replacement therapy, LCIS lobular carcinoma in situ, MBI molecular breast imaging
  2. Note: Unless otherwise noted, data are number of patients and data in parentheses are percentages
  3. aData are mean ± SD. Data in parentheses are ranges.
  4. bExact matches
  5. cData are among postmenopausal women only (49 breast cancer cases, 141 controls)